UNIVERSAL ANTIGEN PRESENTING CELLS AND THEIR USE Russian patent published in 2023 - IPC C12N5/783 A61K35/12 A61K35/17 A61K38/20 

FIELD: biotechnology.

SUBSTANCE: antigen presenting cell (APC) modified to express and contain CD48, membrane-bound interleukin-21 (mbIL-21) and 41BB ligand (41BBL) is described. Also the following is described: APC modified to express and contain CS1 (CD319), mbIL-21 and 41BB ligand (41BBL) and APC modified to express and contain CD48, CS1 (CD319), mbIL-21 and 41BB ligand (41BBL). The following is presented: a method of propagating immunocytes which includes culturing immunocytes in the presence of an effective amount of any of the specified APCs. A population of expanded immunocytes is presented, where the population of cells has improved tumor killing; and, where cells secrete type I cytokines such as interferon-γ, tumor necrosis factor-α and granulocyte-macrophage colony-stimulating factor (GM-CSF). The following is described: a method of treating a disease or disorder in a subject, comprising administering a therapeutically effective number of expanded immunocytes, wherein the therapeutically effective number of expanded immunocytes is between about 10⁵ and about 10¹⁰ cells per dose in a series of dosing cycles.

EFFECT: invention expands the arsenal of means for treating diseases or conditions associated with the presence of a tumor.

58 cl, 4 dwg, 1 tbl, 1 ex